CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will present at two investor conferences in November:
- November 15 – Jefferies London Healthcare Conference at the Waldorf Hilton in London at 4:00 p.m. GMT/11:00 a.m. EST
- November 28 – Evercore ISI 2018 Healthcare Conference at the Boston Harbor Hotel in Boston, at 10:15 a.m. EST
A live audio webcast of the presentation and an archive for replay will be available for both conferences on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replays will be available for 90 days following the live presentations.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers as well as the BET inhibitor CPI-0610 for the treatment of myelofibrosis. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
MacDougall Biomedical Communications